Bard Associates’s Eterna Therapeutics ERNA Stock Holding History

Bard Associates’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18	Closed	-$404K	–	158
2020 Q1	$404K	Hold	18	–	–	0.3%	97
2019 Q4	$596K	Hold	18	–	–	0.3%	98
2019 Q3	$920K	Sell	18 -1	-5%	-$45K	0.47%	81
2019 Q2	$1.07M	Buy	+19	New	+$996K	0.53%	68
2019 Q1	–	Hold	0	–	–	–	69
2018 Q4	–	Hold	0	–	–	–	93
2018 Q3	–	Hold	0	–	–	–	63
2018 Q2	–	Hold	0	–	–	–	68
2018 Q1	–	Hold	0	–	–	–	152

Other funds holding ERNA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NSIM

North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bard Associates's ERNA Position: Q2 2020 in Review

Bard Associates sold out of Eterna Therapeutics (ERNA) in Q2 2020, closing a stake of 18 shares — an estimated $404K sold.

Bard Associates first reported a position in ERNA in Q2 2019 and held it in 4 quarters. The position peaked at $1.07M in Q2 2019. 6 funds tracked by Wall St. Rank hold ERNA as of Q2 2020.

Bard Associates reported no remaining Eterna Therapeutics position as of Q2 2020 after selling out during the quarter.
Bard Associates sold 18 Eterna Therapeutics shares in Q2 2020, an estimated $404K.
Bard Associates first reported a position in Eterna Therapeutics in Q2 2019 and held it in 4 quarters.
Bard Associates's Eterna Therapeutics position peaked at $1.07M in Q2 2019.
6 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2020.

Based on Bard Associates's 13F filing for Q2 2020, filed 13 Aug 2020.